Premier Biomedical, Inc.
BIEI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | 0.00 | 0.00 | 0.88 |
| FCF Yield | 0.00% | -17.29% | 0.06% | -0.15% |
| EV / EBITDA | -23.03 | -9.08 | -313.97 | -767.19 |
| Quality | ||||
| ROIC | 2.91% | 8.94% | 0.99% | 0.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | -0.06 | 0.13 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | -5,927.98% | 158.68% | 92.98% |
| Safety | ||||
| Net Debt / EBITDA | -10.58 | -3.30 | -26.05 | -87.20 |
| Interest Coverage | -1.38 | -5.52 | -0.59 | -0.20 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -53,674.90 |